← Issue №16/ week of Oct 18, 2026/Endoscopy

A Novel Quantitative Endoscopic Tumor Regression Grading System for Predicting Pathological Response Following Neoadjuvant Therapy in Rectal Cancer.

From GI Signals issue №16: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Endoscopy retrospective · n=127 · Oct 15, 2026 · Dis Colon Rectum · IF 3.5

A Novel Quantitative Endoscopic Tumor Regression Grading System for Predicting Pathological Response Following Neoadjuvant Therapy in Rectal Cancer.

Diagnosticcolorectal cancerendoscopy qualitycomputer-aided detectionbiomarker
Clinical takeawayA weighted endoscopic regression grade from one centre, not yet externally validated; organ-preservation decisions after total neoadjuvant therapy still rest on combined endoscopic, MRI and digital assessment of clinical complete response.
What it foundThe Endoscopic Tumor Regression Grading system, classifying patients into Endoscopic Tumor Regression Grading 1 (complete), Endoscopic Tumor Regression Grading 2 (near complete), or Endoscopic Tumor Regression Grading 3 (partial/incomplete), predicted pathological complete response with excellent interobserver agreement (weighted κ = 0.9) and 88.2% exact agreement.
ContextThis retrospective cohort study introduces a novel, statistically weighted endoscopic scoring system, addressing the lack of standardized quantitative assessment tools in current practice, which rely on subjective clinical impressions.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Erkaya M … Gorgun E · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
← Read the whole of issue №16 Every paper GI Signals surfaces gets a page like this one. All issues